title: What happened to the coxibs on the way to the cardiologist?
authors.forename: David S
authors.initials: DS
authors.lastname: Alberts
authors.forename: John D
authors.initials: JD
authors.lastname: Potter
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Martinez
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Hess
authors.forename: Alison
authors.initials: A
authors.lastname: Stopeck
authors.forename: Peter
authors.initials: P
authors.lastname: Lance
mesh_terms: D002309:Cardiology / Q000639:trends; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014481:United States
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib